Quantcast
Home > Quotes > CABA

Cabaletta Bio, Inc. Common Stock (CABA) Quote & Summary Data

CABA 
$17.63
*  
0.16
0.92%
Get CABA Alerts
*Delayed - data as of Jan. 27, 2020  -  Find a broker to begin trading CABA now
Exchange:NASDAQ
Industry: Health Care
View:    CABA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
22
Today's High / Low
$ 18 / $ 17.47
Share Volume
77,333
50 Day Avg. Daily Volume
103,304
Previous Close
$ 17.47
52 Week High / Low
$ 18.28 / $ 7.555
Market Cap
423,719,808
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
77,333
50 Day Avg. Daily Volume:
103,304

Trading Range

The current last sale of $17.63 is 133.36% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18 $ 18.28
 Low: $ 17.47 $ 7.555

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Our lead CAAR T cell product candidate was designed based on chimeric antigen receptor, or CAR, T cell technology that has been successfully developed and is marketed for the treatment of B cell cancers. We believe our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation platform, called our CABA platform, has applicability across over two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized.  ... More ...  



Risk Grade

Where does CABA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 17.47
Open Date:
Jan. 27, 2020
Close Price:
$ 17.63
Close Date:
Jan. 27, 2020


Consensus Recommendation

Analyst Info